Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Notes Payables (2016 - 2020)

Viridian Therapeutics, Inc.\DE has reported Notes Payables over the past 7 years, most recently at $4.7 million for Q3 2020.

  • Quarterly results put Notes Payables at $4.7 million for Q3 2020, down 49.01% from a year ago — trailing twelve months through Sep 2020 was $4.7 million (down 49.01% YoY), and the annual figure for FY2019 was $4.0 million, up 73.32%.
  • Notes Payables for Q3 2020 was $4.7 million at Viridian Therapeutics, Inc.\DE, up from $3.4 million in the prior quarter.
  • Over the last five years, Notes Payables for VRDN hit a ceiling of $10.0 million in Q1 2018 and a floor of $289000.0 in Q2 2018.
  • Median Notes Payables over the past 5 years was $2.3 million (2018), compared with a mean of $3.7 million.
  • Biggest five-year swings in Notes Payables: plummeted 85.4% in 2018 and later surged 1273.7% in 2019.
  • Viridian Therapeutics, Inc.\DE's Notes Payables stood at $2.0 million in 2016, then skyrocketed by 403.91% to $9.9 million in 2017, then tumbled by 76.88% to $2.3 million in 2018, then surged by 73.32% to $4.0 million in 2019, then increased by 18.39% to $4.7 million in 2020.
  • The last three reported values for Notes Payables were $4.7 million (Q3 2020), $3.4 million (Q2 2020), and $7.4 million (Q1 2020) per Business Quant data.